Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Pieris Pharmaceuticals
Pieris Pharmaceuticals
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Media
Merck is set to lead pharmaceutical licensing deals in 2018
GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Media
Pieris Pharmaceuticals appoints new Chairman for Board of Directors
Pharmaceutical
Pieris Pharmaceuticals appoints James Geraghty to its Board of Directors
Regulatory
Commercialised anticalin inhaled treatments
Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients
Pieris announces first cancer immunotherapy collaboration
Agreement with Roche leverages proprietary Anticalin technology platform
Pharmaceutical
Pieris Pharmaceuticals appoints Chief Development Officer
Louis Matis takes up the position at the biotechnology company
Research & Development
Pieris Pharmaceuticals and the University of Melbourne receive grant
To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Subscribe now